2. Business Combinations

On December 30, 2010, we acquired all of the outstanding shares of US Oncology Holdings, Inc. ("US Oncology") for approximately $2.1 billion, consisting of cash consideration of $0.2 billion, net of cash acquired, and the assumption of liabilities with a fair value of $1.9 billion. The cash paid at acquisition was funded from cash on hand. As an integrated oncology company, US Oncology is affiliated with community-based oncologists, and works with patients, hospitals, payers and the medical industry across all phases of the cancer research and delivery continuum. The acquisition of US Oncology expands our existing specialty pharmaceutical distribution business and adds practice management services for oncologists.

The following table summarizes the preliminary recording of the fair values of the assets acquired and liabilities assumed as of the acquisition date:


(In millions)		Amounts Previously Recognized as of Acquisition Date (Provisional)⁽¹⁾		Measurement Period Adjustments			Amounts Recognized as of Acquisition Date (Provisional as Adjusted)
Current assets, net of cash acquired	$	662	$		(7)	$	655
Goodwill		808			12		820
Intangible assets		1,007			(14)		993
Other long-term assets		354			(3)		351
Current liabilities		(489)			(1)		(490)
Current portion of long-term debt		(1,735)			—		(1,735)
Other long-term liabilities		(338)			14		(324)
Other stockholders' equity		(25)			(1)		(26)
Net assets acquired, less cash and cash equivalents	$	244	$		—	$	244

^{(1) As previously reported in our Form 10-K for the year ended March 31, 2011.}

During the second quarter of 2012, the fair value measurements of assets acquired and liabilities assumed of US Oncology as of the acquisition date were revised. The measurement period adjustments during the second quarter of 2012 did not have a significant impact on our condensed consolidated statements of operations, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. These amounts are subject to change within the measurement period as our fair value assessments are finalized. We expect to finalize our fair value assessments by the third quarter of 2012. Financial results for US Oncology have been included in the results of operations within our Distribution Solutions segment beginning in the fourth quarter of 2011.

During the last two years, we also completed a number of other smaller acquisitions within both of our operating segments. Financial results for our business acquisitions have been included in our condensed consolidated financial statements since their respective acquisition dates. Purchase prices for our business acquisitions have been allocated based on estimated fair values at the date of acquisition.

Goodwill recognized for our business acquisitions is generally not expected to be deductible for tax purposes. Pro forma results of operations for our business acquisitions have not been presented because the effects were not material to the condensed consolidated financial statements on either an individual or an aggregate basis.